OrbiMed’s Novavax NVAX Stock Holding History

OrbiMed’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-45,580	Closed	-$9.45M	–	170
2021 Q3	$9.45M	Sell	45,580 -154,715	-77%	-$34.1M	0.1%	130
2021 Q2	$42.5M	Buy	200,295 +44,462	+29%	+$8.15M	0.43%	63
2021 Q1	$28.3M	Buy	+155,833	New	+$31.1M	0.26%	84

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed's NVAX Position: Q4 2021 in Review

OrbiMed sold out of Novavax (NVAX) in Q4 2021, closing a stake of 45,580 shares — an estimated $9.45M sold.

OrbiMed first reported a position in NVAX in Q1 2021 and held it in 3 quarters. The position peaked at $42.5M in Q2 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

OrbiMed reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
OrbiMed sold 45,580 Novavax shares in Q4 2021, an estimated $9.45M.
OrbiMed first reported a position in Novavax in Q1 2021 and held it in 3 quarters.
OrbiMed's Novavax position peaked at $42.5M in Q2 2021.
429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.